Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
SciSparc Ltd. CEO and CFO Adler Oz filed a Form 3 reporting his equity holdings in the company. He directly holds 11,058 Ordinary Shares. He also holds a stock option covering 6 Ordinary Shares at an exercise price of 21294.0000, which is fully vested and expires on March 1, 2028.
The filing notes additional equity that may be received through restricted share units. These RSUs cover 10,000 Ordinary Shares vesting in equal quarterly installments of 1,250 shares beginning on March 18, 2026, and 396 Ordinary Shares vesting in equal quarterly installments of 50 shares beginning on September 30, 2024. Each RSU entitles him to receive one Ordinary Share.
SciSparc Ltd. director Weiss Amitay reported initial holdings of 11,058 Ordinary Shares, held directly. This amount includes 10,000 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 1,250 shares beginning on March 18, 2026, and 396 Ordinary Shares from restricted share units vesting in equal quarterly installments of 50 shares beginning on September 30, 2024. Amitay also holds a stock option, fully vested on April 21, 2024, to acquire 6 Ordinary Shares at an exercise price of 21294.0000 per share, expiring on March 1, 2028.
SciSparc Ltd. director Vider Lior has reported initial ownership holdings. The filing shows direct holdings of 3,651 Ordinary Shares and a stock option for 1 Ordinary Share with an exercise price of 21,294.0000, expiring on March 1, 2028 and fully vested on April 21, 2024.
The footnotes explain additional equity incentives through restricted share units. These cover 3,333 Ordinary Shares vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares vesting in equal quarterly installments of 15 shares beginning on September 30, 2024, with each RSU representing one Ordinary Share.
SciSparc Ltd. Chief Technology Officer Adi Zuloff-Shani filed an initial ownership report detailing current equity interests. The filing shows direct beneficial ownership of 5,528 Ordinary Shares, which includes 5,198 shares subject to restricted share units that vest in scheduled quarterly installments.
The report also lists a fully vested stock option to acquire 6 additional Ordinary Shares at an exercise price of 21,294.0000 per share, expiring on March 1, 2028. This Form 3 is a disclosure of existing holdings and compensation awards, not a report of new share purchases or sales.
SciSparc Ltd. director Liat Sidi filed an initial ownership report, disclosing direct holdings of 3,651 Ordinary Shares. This figure includes 3,333 Ordinary Shares issuable from restricted share units (RSUs) vesting in equal quarterly installments of 417 shares beginning on March 18, 2026, and 120 Ordinary Shares issuable from RSUs vesting in equal quarterly installments of 15 shares beginning on September 30, 2024. Each RSU represents the right to receive one Ordinary Share. The filing also notes a fully vested stock option to buy 1 Ordinary Share at an exercise price of 21,294, expiring on March 1, 2028.
SciSparc Ltd. reports a Schedule 13G filing: Ronen Fatal discloses beneficial ownership of 5% or less of the companys Ordinary Shares as of 12/31/2025.
The filing lists the reporting person as Ronen Fatal, citizenship Israel, and gives his business/residence address in Ramat Gan. The cover references items 5-11 for exact beneficial ownership and dispositive power details. The form is signed on 03/16/2026.
SciSparc Ltd. filing: Eli Zamir submitted a Schedule 13G reporting beneficial ownership of 5 percent or less of a class of Ordinary Shares as of 12/31/2025. The cover pages are incorporated by reference and the form is signed on 03/16/2026.
SciSparc Ltd. reported that its majority-owned subsidiary NeuroThera Labs Inc., in collaboration with Clearmind Medicine Inc., has led to a patent application in Hong Kong for a new therapy to treat major depressive disorder. Clearmind filed the patent for a combination of its proprietary MEAI compound with Palmitoylethanolamide (PEA) sourced by NeuroThera. SciSparc holds an approximately 75% controlling interest in NeuroThera. The companies describe this MEAI‑PEA approach as a non‑hallucinogenic neuroplastogen that may offer a more accessible, safer and affordable alternative to existing antidepressants for depression, a condition affecting more than 332 million people globally.
SciSparc Ltd., through its 75%-owned subsidiary NeuroThera Labs, has signed a definitive agreement to acquire approximately 54.01% of CliniQuantum for 56,375 CliniQ shares in exchange for 56,600,000 NeuroThera common shares valued at about $9,459,954.20. The deal includes potential earn-out payments of up to $2,500,000 over three years based on new patent filings and future fundraising proceeds. NeuroThera will also issue 2,829,999 shares as finder’s fees. After closing, SciSparc’s stake in NeuroThera is expected to decrease from roughly 75% to 43.86%. Separately, NeuroThera announced publication of an international patent application with Clearmind Medicine for a MEAI‑PEA combination therapy targeting obesity and fatty liver disease.
SciSparc Ltd. files an Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 5% or less in its Ordinary Shares. The cover data dated 12/31/2025 and the signature dated 03/09/2026 show the reporting person Nissim Daniel is an Israeli citizen and lists 0.00 for sole and shared voting and dispositive power on the cover. The amendment states the position is ownership of 5 percent or less of a class and incorporates the cover-page items for exact beneficial-ownership figures.